Abstract
Prolyl oligopeptidase (POP) is a serine protease that cleaves peptides shorter than 30-mer at the carboxyl side of an internal proline. POP has been proposed to be involved in some pathologies including mood disorders and neurodegenerative diseases. However, the physiological role of POP remains unknown. To validate POP as a drug target, it is essential to obtain a thorough understanding of its function in vivo. Identification of physiological substrates and products of POP is an important step towards this goal. Recent peptidomic studies have revealed some biological substrates of POP and have given information about the in vivo consequences of POP inhibition. The aim of this review it is to evaluate new advances in this research area and to critically confront these data with initial conclusions and proposals. It seems that substantial activity of POP occurs intracellularly in contrast to the previously proposed role of this peptidase on the direct degradation of extracellular neuropeptides.
Keywords: Prolyl oligopeptidase, prolyl endopeptidase, peptidomics, neuropeptides, peptide metabolism, Somatostatin-28, JTP-4819, GABA, Ac-SDKP, Chronic Obstructive Pulmonary Disease, Radioimmunoassay, iTRAQ, Neurogranin, Haemoglobin, Prosaas
CNS & Neurological Disorders - Drug Targets
Title: Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
Volume: 10 Issue: 3
Author(s): Jofre Tenorio-Laranga, Pekka T. Mannisto and J. Arturo Garcia-Horsman
Affiliation:
Keywords: Prolyl oligopeptidase, prolyl endopeptidase, peptidomics, neuropeptides, peptide metabolism, Somatostatin-28, JTP-4819, GABA, Ac-SDKP, Chronic Obstructive Pulmonary Disease, Radioimmunoassay, iTRAQ, Neurogranin, Haemoglobin, Prosaas
Abstract: Prolyl oligopeptidase (POP) is a serine protease that cleaves peptides shorter than 30-mer at the carboxyl side of an internal proline. POP has been proposed to be involved in some pathologies including mood disorders and neurodegenerative diseases. However, the physiological role of POP remains unknown. To validate POP as a drug target, it is essential to obtain a thorough understanding of its function in vivo. Identification of physiological substrates and products of POP is an important step towards this goal. Recent peptidomic studies have revealed some biological substrates of POP and have given information about the in vivo consequences of POP inhibition. The aim of this review it is to evaluate new advances in this research area and to critically confront these data with initial conclusions and proposals. It seems that substantial activity of POP occurs intracellularly in contrast to the previously proposed role of this peptidase on the direct degradation of extracellular neuropeptides.
Export Options
About this article
Cite this article as:
Tenorio-Laranga Jofre, T. Mannisto Pekka and Arturo Garcia-Horsman J., Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653841
DOI https://dx.doi.org/10.2174/187152711794653841 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Classes of AChE Inhibitors with Additional Pharmacological Effects of Interest for the Treatment of Alzheimers Disease
Current Pharmaceutical Design A Proteomic Analysis of Mitochondrial Complex III Inhibition in SH-SY5Y Human Neuroblastoma Cell Line
Current Proteomics The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease
Current Alzheimer Research Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)
Current Medicinal Chemistry Systems Biology Approach for the Identification of Diagnostic and Therapeutic Targets in Medulloblastomas
Current Pharmacogenomics and Personalized Medicine Phenolic and Organic Acids from <i>Spondias pinnata</i> Fruits
The Natural Products Journal Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway
Current Alzheimer Research Editorial [Hot topic: Sigma1 and Sigma 2 Receptors (Guest Editor: Richard A. Glennon)]
Central Nervous System Agents in Medicinal Chemistry Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Decoding the Inter-Relationship between Sleep Disorders and Alzheimer’s Disease Pathogenesis
CNS & Neurological Disorders - Drug Targets No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry